Snapshot · Zoetis Inc. (ZTS)

Data as of 2026-09-01T06:41:46.189Z

Fundamentals check

Market cap

$32.3B

P/E (TTM)

12.7

Gross margin

70.9%

Net margin

27.5%

ROE

69.3%

R&D / revenue

7.6%

Dividend yield

2.7%

FCF yield

7.3%

Latest dividend: $0.53/share (ex-date 2026-07-20, quarterly)

Summary

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

How it makes money

Revenue mix, latest fiscal year

• Horses67.8%
• Cattle16.1%
• Swine5%
• Poultry4.7%
• Dogs and Cats3.3%
• Fish3.1%

Recent Events

• 2026-08-19T00:00:00.000Zpositive

  Price move: ZTS rose 3.7%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-18T04:38:42.000Zpositive

  Zoetis: A Solid Long-Term Buy After Harsh Drawdown

  长期看好但基于分析观点，可能与市场估值修复相关，尚不足以确立因果关系。

  Source: seekingalpha.com

• 2026-08-13T15:51:00.000Zpositive

  Zoetis Receives Emergency Use Authorization for Simparica Trio® for Treatment of New World Screwworm Infestations in Dogs and Puppies

  FDA 急救使用授权可能对相关产品线产生积极影响，属于可能相关的推动因素，尚需后续证据。

  Source: businesswire.com

• 2026-08-11T01:21:32.000Znegative

  Zoetis Hits New 1-Year Low on Analyst Downgrade

  分析师下调目标可能与市场情绪下降相关，尚不能确认因果关系为股价下跌的唯一原因。

  Source: defenseworld.net

• 2026-08-07T00:00:00.000Znegative

  Price move: ZTS fell 6.0%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-06T14:10:47.000Znegative

  Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate Headwinds

  头条显示需求放缓，可能与市场情绪相关，但未确认直接因果关系。

  Source: benzinga.com

• 2026-08-06T13:06:05.000Zmixed

  Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

  财报对盈利利好但营收与前景指引下调，可能反映公司运营压力的信号，但不构成直接因果结论。

  Source: zacks.com

• 2026-08-06T00:00:00.000Zneutral

  ZTS filed 8-K

  该新闻可能与公司披露内容相关，暂不可断定因果关系，但对后续观察有提示性作用。

  Source: SEC EDGAR

• 2026-07-16T00:00:00.000Zpositive

  Price move: ZTS rose 3.2%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-02T00:00:00.000Zpositive

  Price move: ZTS rose 3.2%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-29T00:00:00.000Znegative

  Price move: ZTS fell 3.7%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-09T00:00:00.000Zpositive

  Price move: ZTS rose 4.3%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $88.5 from 8 analysts (last quarter)

Insider & Congress activity

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。